SciClone And Sigma-Tau Provide Update On Phase 3 Hepatitis C Study
Jun 30th 2008Drug InformationLiver Disease / Hepatitis
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) and Sigma-Tau S.p.A. announced that all 553 enrolled patients successfully completed a Phase 3 trial. After 48 weeks of therapy, all patients responding to treatment have now completed their 24-week follow-up. The unblinded data from the trial are expected to be available in the fourth quarter of 2008.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
